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Abstract  
Background 
Loss of heterozygosity (LOH) is an important marker for one of the ‘two-hits’ required for tumor suppressor gene 
inactivation. Traditional methods for mapping LOH regions require the comparison of both tumor and patient-matched 
normal DNA samples. However, for many archival samples, patient-matched normal DNA is not available leading to 
the under-utilization of this important resource in LOH studies. Here we describe a new method for LOH analysis that 
relies on the genome-wide comparison of heterozygosity of single nucleotide polymorphisms (SNPs) between 
cohorts of cases and healthy control samples. Regions of LOH are defined by consistent decreases in heterozygosity 
across a genetic region in the case cohort compared to the control cohort.  
Methods 
DNA was collected from 20 Follicular Lymphoma (FL) tumor samples, 20 Diffuse Large B-cell Lymphoma (DLBCL) 
tumor samples, neoplastic B-cells of 10 B-cell Chronic Lymphocytic Leukemia (B-CLL) patients and Buccal cell 
samples matched to 4 of these B-CLL patients. The cohort heterozygosity comparison method was developed and 
validated using LOH derived in a small cohort of B-CLL by traditional comparisons of tumor and normal DNA 
samples, and compared to the only alternative method for LOH analysis without patient matched controls. LOH 
candidate regions were then generated for enlarged cohorts of B-CLL, FL and DLBCL samples using our cohort 
heterozygosity comparison method in order to evaluate potential LOH candidate regions in these non-Hodgkin’s 
lymphoma tumor subtypes. 
Results 
Using a small cohort of B-CLL samples with patient-matched normal DNA we have validated the utility of this method 
and shown that it displays more accuracy and sensitivity in detecting LOH candidate regions compared to the only 
alternative method, the Hidden Markov Model (HMM) method. Subsequently, using B-CLL, FL and DLBCL tumor 
samples we have utilised cohort heterozygosity comparisons to localise LOH candidate regions in these subtypes of 
non-Hodgkin’s lymphoma. Detected LOH regions included both previously described regions of LOH as well as novel 
genomic candidate regions. 
Conclusions 
We have proven the efficacy of the use of cohort heterozygosity comparisons for genome-wide mapping of LOH and 
shown it to be in many ways superior to the HMM method. Additionally, the use of this method to analyse SNP 
microarray data from 3 common forms of non-Hodgkin’s lymphoma yielded interesting tumor suppressor gene 
candidates, including the ETV3 gene that was highlighted in both B-CLL and FL.  
Background  
The elimination of tumor suppressor gene (TSG) function contributes to carcinogenesis and 
cancer progression. Early work on the RB1 gene locus suggested two hits in TSGs were 
required to disrupt TSG function [1,2]. That is, both alleles of a TSG must be interrupted by 
mutation or allelic loss in order to render it inactive. Loss of heterozygosity (LOH), the 
transition from germ-line heterozygosity at a polymorphic locus to somatic homozygosity, is a 
hallmark of allelic loss and thus represents one of the two hits required for TSG inactivation. 
 
Analysis of LOH is therefore important in cancer research in order to localize potential TSGs 
that may have a role in disease genesis and progression [3]. The introduction of high-density 
single nucleotide polymorphism (SNP) arrays has allowed high-resolution mapping of LOH 
and the delineation of minimally lost regions that indicate the presence of important TSGs [4]. 
The conventional method for LOH analysis relies on the comparison of SNP genotypes 
between tumor DNA samples and patient-matched control (germ-line) DNA samples obtained 
from normal (non-tumor) tissue. Unfortunately, many archived tumor samples are not 
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accompanied by patient-matched control tissue resulting in the under-utilization of these 
potentially valuable resources for LOH analysis.  
 
Recently, an alternative method was described that utilizes a hidden Markov model (HMM) to 
infer the presence of LOH in non-matched tumor samples by the absence of heterozygosity 
[5]. This method utilizes long strings of SNPs with homozygous calls to infer LOH and 
generates high numbers of candidate regions spanning large genetic distances. In order to 
overcome this limitation and increase the resolution of LOH mapping, we have developed a 
method to infer the presence of LOH regions through the comparison of SNP heterozygosity 
values between case and reference cohorts (Cohort Heterozygosity Comparison; CHC). The 
CHC method infers LOH candidate regions by the presence of short strings of SNPs which 
exhibit consistently lower prevalence of heterozygosity in the case cohort compared to the 
control cohort. The method is based on the hypothesis that decreased heterozygosity of 
closely spaced SNPs in the case cohort compared to the control cohort indicates a region of 
LOH. The CHC method calculates heterozygosity values for SNPs covering the entire 
genome in case and control cohorts, and then identifies and recovers the data from 
informative SNPs. By directly comparing heterozygosity of informative SNPs, groups of SNPs 
with significant differences in heterozygosity between the cohorts can be identified.  
 
In this study, the CHC method was employed using SNP data from Affymetrix 250K SNP 
arrays to infer LOH regions in tumor samples from B-cell Chronic Lymphocytic Leukemia (B-
CLL), Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) patients. SNP 
array data from patient-matched buccal samples from four of the B-CLL patients was initially 
used to definitively map LOH by conventional methods in order to determine regions that will 
henceforth be referred to as ‘conventional LOH’. These ‘conventional LOH’ regions were used 
in order to validate ‘inferred LOH’ regions generated by the CHC method. Validation of 
‘conventional LOH’ was additionally performed by high-density microsatellite analysis. This 
work, as well as direct comparison of the efficacy of the CHC method with that of the only 
alternative (HMM) method, highlighted the utility of cohort heterozygosity comparisons for 
mapping LOH candidate regions without the need for patient-matched control samples. We 
therefore performed CHC analysis on larger numbers of FL, DLBCL and B-CLL samples in 
order to elucidate LOH candidate regions with potential roles in disease pathogenesis. 
Methods 
Patient Samples and DNA Extraction 
Ethical approval for this work was obtained from the Human Research Ethics committees of 
Griffith University, the Gold Coast Hospital and the Princess Alexandra Hospital. Peripheral 
blood samples were obtained from B-CLL patients (n=10) through the Prince Charles and 
Gold Coast Hospitals. Lymphocytes were enriched from 3mL of whole-blood using 
ACCUSPIN™ system HISTOPAQUE®-1077 columns (Sigma-Aldrich) according to the 
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manufacturer’s protocol and B-cells were isolated from lymphocyte enrichments using 
Dynabeads® CD19 (Invitrogen) and a magnetic particle concentrator according to the 
manufacturer’s protocol. Following isolation of B-cells, the cells were lysed by the addition of 
600µL of lysis buffer (Qiagen) and passing through a 20-guage needle. DNA was purified 
from lysed cells using QIAamp DNA Tissue Mini Kits according to the manufacturer’s 
protocol. Buccal cell samples were collected from 4 of the B-CLL patients using Catch-All 
sample collection swabs (Epicentre Biotechnologies), and DNA isolated using BuccalAmp 
DNA extraction kits (Epicentre Biotechnology) according to the manufacturer’s protocol. 
 
FL (n=20) and DLBCL (n=20) tumor specimens were obtained through the Australian 
Leukemia and Lymphoma Group (ALLG) Tissue Bank (Princess Alexandra Hospital, 
Queensland, Australia) and BioOptions BioRepository Service (http://www.biooptions.com/). 
DNA was extracted from tumor tissue using a modified column extraction protocol. 10mg of 
tissue was homogenized in 1mL of phosphate-buffered saline (pH 7.4) using a rotor-strator 
homogenizer. Protein was digested by incubation with Proteinase-K at 70°C for 30min. DNA 
was purified from the milieu using QIAamp DNA Blood Midi Kit (Qiagen) according to the 
manufacturers protocol and all samples that were below a concentration of 100ng/µL were 
precipitated in ethanol and re-eluted in a smaller volume. 
Single Nucleotide Polymorphism Microarrays 
DNA samples were amplified, fragmented, labelled and hybridized to Affymetrix 250K Sty 
SNP microarrays in accordance with the manufacturer’s protocol. Raw data was extracted 
from image files using GeneChip Operating System software (GCOS; Affymetrix). SNP 
genotyping and HMM-based LOH analysis was performed using GeneChip Genotyping 
Software (GTYPE; Affymetrix). ‘Conventional LOH’ was detected in 4 B-CLL patients by 
comparison of SNP microarray genotypes from Buccal and tumor samples. This was 
performed using dChipSNP software as previously described [6]. 
Microsatellite Analysis of LOH 
Case tumor and buccal DNA samples were amplified using the Illustra Genomiphi V2 DNA 
amplification kit (GE Healthcare) according to the manufacturer’s protocol. Each sample was 
genotyped at the Australian Genome Research Facility (AGRF, Sydney, Australia) using a 
standardized set of 63 microsatellites markers for chromosome 1. These markers span 
chromosome 1 with an average resolution of 5cM (http://appliedbiosystems.com/apps/). 
Evaluation and Statistical Analysis of ‘Inferred LOH’ Regions 
In order to evaluate the ‘Inferred LOH’ regions generated by CHC and HMM methods, 
annotation data from the Affymetrix GeneChip® Genotyping Software was analyzed in 
Microsoft Excel. Each inferred LOH region was then plotted on the spreadsheet and 
evaluated for size and distance from SNPs showing ‘conventional LOH’. Size was calculated 
using the physical position of the SNPs at the end of each region. The distance from 
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‘conventional LOH’ was calculated using the physical positions of the SNPs at the end of 
each region and the physical position of the closest SNP showing ‘conventional LOH’. If 
candidate regions encompassed SNPs showing ‘conventional LOH’, the distance to the 
closest ‘conventional LOH’ was determined to be 0.  
 
Normality of the distribution of delta values was tested using Blom’s formula in order to 
ensure the correct model was being employed for power analysis. To establish differences in 
sensitivity and specificity of the CHC method with different contiguous point thresholds (CPT), 
correlations between CPT and the percentage of regions encompassing ‘conventional LOH’ 
or the distance of regions from ‘conventional LOH’ were derived using Pearsons correlation 
and the full data set for each CPT. In order to illustrate the fact that the primary determining 
factor for the distance of LOH regions inferred by CHC from the ‘conventional LOH’ was the 
resolution of the SNPs within the region, Pearsons correlation was used to compare the 
distance from the closest SNP showing ‘conventional LOH’ and the distance between SNPs. 
Only the ‘inferred LOH’ regions derived with a CPT of 5, and that did not encompass markers 
showing ‘conventional LOH’ (n = 159) were employed for this analysis. Demonstration of the 
need for the CHC method to have high heterozygosity frequencies at SNPs  showing 
‘conventional LOH’ in order to map LOH candidate regions over them when employing small 
cohort samples sizes was achieved by comparison of heterozygosity frequencies of SNPs 
showing ‘conventional LOH’ found inside candidate regions compared to those adjacent to 
candidate regions. This was achieved through the use of an independent-samples Students 
T-test of all regions generated with a CPT of 5. In order to highlight the utility of the 
enrichment score (ES) generated from the sum of delta values, Pearsons correlation was 
used to correlate the ES values of all ‘inferred LOH’ regions generated with a CPT of 5 with 
the distance of each region from the closest SNP showing ‘conventional LOH’. To evaluate 
the efficacy of the HMM method, the percentage of HMM candidate regions that 
encompassed SNPs showing ‘conventional LOH’ was compared between patients by one-
way ANOVA with Bonferroni post-hoc analysis.  
Cohort Heterozygosity Comparison Analysis of B-CLL, FL and DLBCL Samples 
SNP microarray data for DLBCL, FL and B-CLL samples was analysed using the CHC 
method with reference to data generated from Caucasian HapMap samples. This data is 
freely available from www.affymetrix.com. It should be noted that different control samples 
were used for each NHL disease sub-category in order to avoid biasing the results. In order to 
ensure accuracy of LOH regions, CHC analysis was performed using a delta threshold of 0.4 
and a CPT of 5. Regions of ‘inferred LOH’ were ranked by enrichment score and the top 2 
regions for each subtype discussed. 
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Results 
Algorithm 
Selection of Informative Markers 
Selection of informative SNPs (SNPi) is the first important aspect of the CHC method. As 
heterozygous genotypes are required to infer LOH using both the conventional and CHC 
methods of analysis, it is important that there be a likelihood of obtaining heterozygous 
genotypes within a case cohort. In order to perform cohort comparisons only those markers 
that were predicted to give a heterozygous call within the cohort were deemed to be 
informative; that is, only those markers with a population heterozygosity value (HV) greater 
than or equal to the reciprocal of the cohort size. HV for the given ethnicity is as determined 
by the SNP microarray annotation data.In the initial validation set of four samples in this 
investigation, 55% of the SNPs on the array were selected as informative markers; this 
translates to >125,000 SNPs. But by increasing the sample size in the secondary test sets of 
B-CLL, FL and DLBCL samples, larger numbers of the SNPs were selected as informative. 
Thus, the resolution of this method remains high even with low sample sizes, but is improved 
with increasing sample size due to inclusion of SNPs with lower heterozygosity frequencies.  
n
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Calculation of Delta Values 
Because of the potential to skew case and control heterozygosity values, all markers with 
absent genotype calls in any of the samples were removed from the analysis. Heterozygosity 
values were then calculated for all remaining SNPs for each cohort. A delta value (Δ), 
representative of the difference in heterozygosity value between each cohort, was then 
calculated for each SNP. 
 
)()( CaseControl HVHV  
Calculation of Delta Threshold 
Different cohort sample sizes between investigations also make it important to calculate the 
delta threshold for each application of the CHC method. The statistical power of different 
investigations is dependant upon their respective sample sizes. With increasing sample size, 
a lesser effect size (Δ) is needed in order to obtain statistically significant results, whilst 
maintaining the desired minimum power (80%). The delta threshold is therefore set to 
maintain a statistical power of 80% (α = 0.05). For example, with the initial validation cohort (n 
= 4, σ = 0.3) the delta threshold was calculated to be 0.5, whereas by increasing the sample 
size to 10 in the secondary cohort of B-CLL samples while maintaining the same standard 
deviation the maximum required delta threshold required to obtain 80% power was lowered to 
0.3. This means that with a sample size of 4 a 50% decrease in case cohort heterozygosity 
frequency must be observed in the case cohort compared to the reference cohort in order for 
the marker to be deemed informative, whereas with a sample size of 10 only a 30% decrease 
in case cohort heterozygosity frequency is required for a marker to be deemed informative. 
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Increasing the cohort sample size when using the CHC method of LOH analysis is therefore 
expected to increase the specificity of the method and hence decrease the number of type I 
errors. Statistical power analysis was employed to calculate the delta value required (i.e. 
effect size) to achieve a minimum power of 80% with the specified cohort sample size 
(α=0.05). The following formula was utilized to calculate the delta threshold (ΔT), which was 
used to determine which delta values were suggestive of LOH (ΔS).  
 
n
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T
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Contiguous Point Threshold and Inferring LOH 
The number of contiguous SNPs required to infer LOH within a region is referred to as the 
contiguous point threshold (CPT). Strings of contiguous SNPs larger than or equal to the CPT 
and yielding informative delta values are highlighted as ‘inferred LOH’ regions. By altering this 
threshold users are able to modify the sensitivity and specificity of the CHC method. Using a 
low CPT a comparatively higher number of ‘inferred LOH’ regions can be localized compared 
to using a high CPT. However, this increased sensitivity is accompanied by decreased 
specificity. Setting the CPT is therefore a trade-off between sensitivity and specificity, and 
should be considered for each application of this method. However, it is recommended that a 
minimum CPT of 5 be employed in order to ensure sufficient specificity.  
 
Enrichment Score 
In order to predict the proximity of ‘inferred LOH’ regions to markers showing ‘conventional 
LOH’, an enrichment score can be generated by summing the delta values generated within 
an ‘inferred LOH’ region. This enrichment score negatively correlates with the distance to 
closest ‘conventional LOH’ marker, indicating that the higher the enrichment score the closer 
the ‘inferred LOH’ regions will link to markers showing ‘conventional LOH’. It is therefore 
recommended that the sequence immediately flanking CHC candidate regions with low 
enrichment scores also be considered when searching for candidate TSGs. 
 
SScore  
Automated Analysis using Cohort Heterozygosity Comparison  
A platform for automated CHC analysis, instructions for use, and the case and control input 
files utilized for analysis B-CLL, FL and DLBCL cohorts in this manuscript are available from 
the journal web-site.  
Testing  
Validation of the Cohort Heterozygosity Comparison Method 
Delta values were calculated for each informative SNP as described above. These values 
demonstrated a positively skewed normal distribution, as would be anticipated with decreased 
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heterozygosity frequency in the case cohort. Calculation of the delta threshold is an important 
facet of the CHC method. With increasing cohort sample size a decrease in the effect size (Δ) 
is required to obtain significant results, whilst maintaining 80% power. For the initial validation 
set of B-CLL samples (n=4, σ=0.3) the delta threshold was calculated to be 0.5, for the 
subsequent test set (n=10, σ=0.3) the delta threshold was calculated to be 0.3.  
 
The number of inferred regions for each CPT can be seen in Table 1. From this it can be seen 
that increasing the CPT decreased the number of LOH candidate regions generated via the 
CHC method. A significant positive correlation was found between CPT and the percentage of 
regions that spanned SNPs showing ‘conventional LOH’ (Pearsons correlation coefficient = 
0.998; p = 0.002), and a significant negative correlation was found between CPT and the 
mean distance of ‘inferred LOH’ regions from the closest SNP showing ‘conventional LOH’ 
(Pearsons correlation coefficient = -0.996; p = 0.004). It is therefore predicted that raising the 
CPT increases the selectivity of the CHC method (i.e. decrease the chance of a Type I error), 
but in return may also decrease its sensitivity (i.e. increase the chance of a type II error). 
 
A striking trend was also observed whereby those regions that did not encompass SNPs 
showing ‘conventional LOH’ mapped directly adjacent to them. When evaluating the LOH 
regions inferred with a CPT of 5, those SNPs showing ‘conventional LOH’ that mapped 
directly adjacent to regions of ‘inferred LOH’ were found to have a mean heterozygosity of 
0.19 (n =  159). The mean population heterozygosity of SNPs showing ‘conventional LOH’ 
that mapped inside ‘inferred LOH’ regions was found to be 0.32 (n = 140), and was 
significantly higher than those mapping adjacent to candidate regions (p < 0.001). A positive 
correlation was found between the distance of candidate regions from the closest SNP 
showing ‘conventional LOH’ and the distance between SNPs (Pearsons correlation coefficient 
= 0.290; p = 0.022). A significant negative correlation was found between enrichment score 
and the distance to the closest SNP showing ‘conventional LOH’ (Pearsons correlation 
coefficient = -1.43; p < 0.001). 
 
Evaluation of the Hidden Markov Model Method 
The HMM method for inferred LOH regions, associated with the Affymetrix GeneChip® 
Genotyping Software CNAT 4.0 tool, generates scores of either 1 or 0 relating to ‘inferred 
LOH’ or retention of heterozygosity respectively. Regions with scores of 1 were classified as 
‘inferred LOH’ regions and are summarized in Table 2. This method was found to generate 
large numbers of regions that spanned large genomic distances and that had a variable rate 
of success in encompassing ‘conventional LOH’ in the CLL patients. In total for the four 
cases, 699 regions were selected as regions of ‘inferred LOH’ by the HMM method. Of these, 
82 regions overlapped in two patients, 22 candidate regions overlapped in three patients, and 
2 candidate regions overlapped in all four patients, resulting in 567 independent regions of 
‘inferred LOH’ for follow-up analysis from four cases. A significant difference in the 
percentage of HMM candidate regions encompassing SNPs showing ‘conventional LOH’ was 
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also noted between cases (p = 0.01). No feature of individual case data was found to predict 
the percentage of regions encompassing SNPs showing ‘conventional LOH’.  
Implementation 
After validation of the CHC method, SNP array data for DLBCL, FL and B-CLL samples was 
analysed using the CHC method. This generated 9 LOH candidate regions in DLBCL with 
enrichment scores ranging from 2.1 to 5.45, 10 LOH candidate regions in FL with enrichment 
scores ranging between 2.2 and 4.65, and 65 candidate regions in B-CLL with enrichment 
scores ranging from 2 to 5.8. The top two candidates for each NHL subtype, as assessed by 
enrichment score, are displayed on Table 3. 
Discussion  
We have developed a method for inferring regions of LOH by analyzing cohort heterozygosity 
values using SNP arrays, without the need for patient-matched samples. Initially, LOH regions 
were inferred in a small cohort of B-CLL patients using the Cohort Heterozygosity 
Comparison method. In order to investigate the efficacy of this method, regions of 
‘conventional LOH’ were mapped in these patients through the use of SNP array data from 
patient-matched buccal samples. The mapping of LOH by the conventional method was also 
validated by analysis of 63 microsatellite markers on chromosome 1 in these case and 
patient-matched control samples. Following validation of this novel method of LOH analysis, 
CHC analysis was used to infer LOH in an extended cohort of B-CLL samples as well as 
larger cohorts of FL and DLBCL samples.  
 
The CHC method employs genotype data generated by SNP microarray in order to detect 
regions of decreased heterozygosity frequency in the case cohort compared to the control 
cohort. Markers included on modern high-density SNP arrays are becoming decreasingly 
polymorphic as array resolution expands due to the potential to utilize non-polymorphic 
markers in genome-wide copy number analysis. The CHC method therefore only utilizes 
markers with a predicted capacity to generate at least one heterozygous genotype within 
each of the case and control cohorts. Cohort heterozygosity frequencies are calculated for 
each informative SNP in order to generate delta values that correspond to the difference in 
heterozygosity between cases and controls. Decreases in heterozygosity frequency, as 
demonstrated by a positive delta score, are considered to be suggestive of LOH if they 
exceed a set threshold. This threshold (∆T) is one of the modulatory parameters of the CHC 
method that can be used to alter the balance between sensitivity and specificity. The minimal 
∆T should represent the minimum effect size required in order to obtain a sufficient statistical 
power for the analysis, however it some applications it may be desirable to increase the ∆T in 
order to obtain higher specificity.  
 
The second parameter by which users of the CHC method are able to modulate sensitivity 
and specificity is the contiguous point threshold (CPT). This threshold is used to highlight 
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regions as inferring LOH only if the number of contiguous markers exceeding ∆T is equal to or 
above the CPT. For example, when CPT=5 the CHC method infers LOH in regions containing 
≥5 contiguous points exceeding ∆T. The CPT is applied in order to minimize false positives; 
that is, the implication of regions that contain markers that exceed ∆T but are not associated 
with LOH. The ability of this parameter to modulate the sensitivity and specificity of this 
method was aptly shown by the decreasing number of inferred LOH regions and more 
accurate inference of LOH with increasing CPT, respectively (Table 1).  
 
A caveat of the CHC method when employing small sample sizes is the increased 
requirement for high heterozygosity frequencies in order to detect LOH. This led to a portion 
of the regions within the validation cohort mapping adjacent to, rather than encompassing, 
SNPs showing ‘conventional LOH’. In this investigation the validation cohort sample size was 
modest; meaning that the effect size must be large in order to define regions with significantly 
decreased heterozygosity in the case cohort compared to the control cohort. In the validation 
cohort of 4 samples, when employing a CPT of 5 and a delta threshold of 0.5, there must be 5 
consecutive SNPs with a 50% decrease in heterozygosity between the case and control 
cohorts in order LOH to be inferred. This means the CHC method can only detect LOH in 
small sample sizes if the region of LOH has a high enough initial rate of heterozygosity. In 
instances in which SNPs showing ‘conventional LOH’ had low population heterozygosity, the 
‘inferred LOH’ region frequently mapped directly adjacent to them rather than encompassing 
them. This is supported by the fact that the SNPs showing ‘conventional LOH’ that mapped 
adjacent to regions of ‘inferred LOH’ derived by the CHC method had a significantly lower 
population heterozygosity than those that mapped inside the ‘inferred LOH’ regions. 
Furthermore, the distance of these adjacently positioned regions of ‘inferred LOH’ from 
‘conventional LOH’ was determined primarily by the resolution of markers within each 
respective genomic region. The need for high population heterozygosity frequencies in order 
to map SNPs showing ‘conventional LOH’ within regions of ‘inferred LOH’ generated by the 
CHC method can be alleviated by increasing the cohort sample size. This would augment the 
power of the investigation and decrease the effect size required to define SNPs as being 
suggestive of LOH. However, even with the small sample size in the validation cohort the 
CHC method was shown to successfully infer LOH regions closely to SNPs showing 
‘conventional LOH’, including those with low population heterozygosities. Furthermore, 
utilization of the CHC method with small sample sizes is further aided by the use of 
enrichment scores for each ‘inferred LOH’ region. This score is a sum of the heterozygosity 
frequency delta values, and was shown to significantly and negatively correlate with the 
distance of ‘inferred LOH’ from ‘conventional LOH’. 
 
The only current alternative to the CHC method for mapping LOH without the need for patient-
matched control samples is a method based on an HMM algorithm [5]. This method relies on 
identification of long strings of homozygous SNP genotypes in order to infer LOH. We 
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employed this method to analyze each of the four initial validation case samples in this 
investigation. It yielded 699 candidate regions with an average size of over 95kb between the 
four cases. Only 19% of these candidate regions overlapped in two or more patients, resulting 
in 567 independent genomic regions that were suggestive of LOH. When comparing this to 
the regions inferred by the CHC method with the recommended CPT it can be seen that the 
CHC method delineated regions that were on average over 70% smaller, and more frequently 
mapped within the immediate vicinity of ‘conventional LOH’. The CHC method therefore 
inferred LOH more specifically and within smaller genomic regions than the HMM method. 
 
In order to investigate whether automated analysis of larger samples of NHL patients could 
derive hypothetically important candidates, the CHC method was used to analyze larger 
cohorts B-CLL, FL and DLBCL samples. Using the enrichment score, the top two LOH 
candidate regions for each disease subtype were investigated for candidate genes that may 
possess a hypothetical tumor-suppressor function in NHL. Although one of the regions of 
‘inferred LOH’ in DLBCL mapped over a genetic region with no closely linked coding loci, this 
region (3q11.2) has been shown to be lost in a range of cancers including acute 
lymphoblastic leukemia and mantle cell lymphoma [7,8], and the remaining 5 candidate 
regions were closely linked to attractive TSG candidates. Among these were two DNA repair 
genes (FANCD2, ERCC8), an inhibitor of RAS-mediated transformation (ANP32C), and a 
repressor of NFκB activity that was highlighted in both B-CLL and FL cohorts (ETV3).  
 
The association between DNA repair genes and the pathogenesis of NHL is demonstrated by 
lymphoma predisposition within immunodeficiency cases containing mutations in genes 
mediating DNA damage repair [9] to developing NHL, as well as the numerous associations 
between polymorphisms in DNA repair genes and genetic susceptibility to NHL [10-12]. It is 
therefore not surprising that DNA repair genes may play a central tumor suppressor role in 
NHL. The FANCD2 gene was linked with a region of ‘inferred LOH’ highlighted in the B-CLL 
patient cohort, and functions in by forming complexes with BRCA1 or RAD51 and mediating 
repair of transcriptionally active genes [13]. Furthermore, this gene has also been shown to 
be essential for maintaining the G2 cell-cycle checkpoint [14]. The ERCC8 gene is also 
involved in DNA repair of transcriptionally active genes [15], and was linked with a region of 
inferred LOH in the FL patient cohort. Further support for this gene as a potential TSG is 
provided by the increased frequency of cancer in Cackayne’s syndrome patients in which the 
ERCC8 gene is mutated [15]. The targeting of the FANCD2 and ERCC8 genes by LOH, as 
inferred by the CHC method, indicates that knock-out of their function may allow for the 
accumulation of mutations within transcriptionally active genes. Furthermore this may also be 
compounded by subsequent un-checked progression through the G2 checkpoint without 
FANCD2-associated cell-cycle arrest or apoptotic induction. 
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The ANP32C gene was highlighted as a potential TSG by CHC analysis of the DLBCL patient 
cohort. This gene has been previously described as a tumor suppressor gene, and elucidation 
of its function revealed that this role may be due to repression of RAS-mediated 
tumorigenesis [16]. However, our implication of this gene in the pathogenesis of NHL is a 
completely novel finding. The most interesting finding within the CHC analysis results was the 
revelation of ETV3 as a potential TSG in both B-CLL and FL patient cohorts. This gene is part 
of the ETS-family of tumor suppressors and functions in repression of NFκB-activated 
transcription [17]. LOH of the ETV3 locus at 1q23.1 has been previously demonstrated in B-
CLL [18], and its potential as a TSG is supported by the importance of NFκB signaling in 
promoting proliferation and inhibiting apoptosis within lymphocytes [19]. The implication of 
genes with well defined tumor suppressor roles by cohort heterozygosity comparison of B-
CLL, FL and DLBCL provides evidence that this novel method of analysis infers LOH within 
plausible TSGs. However, in order to provide a definitive evidence for LOH of these genes in 
NHL, microsatellite analysis should be performed within large independent cohorts of 
patients. 
Conclusions  
Analysis of SNP array data from case and unmatched control samples with the CHC method 
was shown to infer LOH regions that linked closely to SNPs showing ‘conventional LOH’. This 
method can be adopted for investigation of varied sample sizes, and the specificity and 
sensitivity of the method can be tailored to suit the objectives of each investigation. The 
candidate regions generated by the CHC method were considerably smaller and mapped 
significantly closer to SNPs showing ‘conventional LOH’ than the candidate regions generated 
by it’s only current alternative, the HMM method. The utility of this method was further 
highlighted by its use to elucidate potentially important regions of LOH in three subtypes of 
NHL, including the ETV3 gene that was highlighted in both B-CLL and FL patient cohorts.  
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Figures 
Tables 
Table 1  - Validation of ‘Inferred LOH’ Regions Generated by the CHC Method 
*’Conventional LOH’  
CPT No. of Regions Mean Region 
Size (bp) 
Regions within 
100kb of LOH* 
Mean Distance 
from LOH* (bp) 
3 1,263 67,145 89% 36,460 
4 594 101,166 92% 30,582 
5 299 119,886 93% 25,220 
6 162 112,431 96% 21,316 
 
Table 2  - Validation of ‘Inferred LOH Regions Generated by the HMM Method 
*’Conventional LOH’ 
Sample No. of Regions Mean Region 
Size (bp) 
Regions within 
100kb of LOH 
Mean Distance 
from LOH (bp) 
1 185 1,123,018 91% 33,850 
2 187 1,003,721 78% 154,242 
3 121 847,306 62% 230,310 
4 206 892,220 97% 5,189 
Total 699 975,359 82% 91,619 
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Table 3  - Top 2 Regions of ‘Inferred LOH’ for each NHL Subtype 
Top ‘inferred LOH’ regions, as determined by enrichment score, showing the 
cytogenetic location, start position and finish position determined by the location of 
first and last SNPs, and the candidate gene determined by annotation data. 
Disease Location Start Position Finish Position ES Candidate 
CLL 1q23.1 155269409 155393832 5.80 ETV3 
CLL 3p25.3 9972054 10143892 5.80 FANCD2 
FL 5q11.2 56022313 67005198 4.65 ERCC8 
FL 1q23.1 155269409 155320805 3.55 ETV3 
DLBCL 3q11.2 96553777 96717069 5.45 - 
DLBCL 4q32.3 165412095 165440501 4.30 ANP32C 
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Perl script for automated analysis using the cohort heterozygosity comparison 
method. 
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Text File containing genotype and annotation data for the extended B-CLL case 
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